What Are the ADA Blood Glucose Goals?

The American Diabetes Association recommends that most nonpregnant adults aim for an A1C below 7%, a preprandial (before-meal) blood glucose of 80 to 130 mg/dL, and a peak postprandial (after-meal) glucose below 180 mg/dL. These numbers serve as the default starting point, but the ADA’s own Standards of Care stress that goals should be individualized. What “good control” looks like shifts depending on your age, how long you have had diabetes, whether you are pregnant, and how your overall health is holding up.

The Standard Numbers for Most Adults

The ADA publishes its Standards of Care in Diabetes every year, and the glycemic targets for most nonpregnant adults have been stable for some time. The three headline numbers are an A1C below 7% (which corresponds to about 53 mmol/mol), a fasting or pre-meal capillary blood glucose of 80 to 130 mg/dL, and a peak post-meal capillary blood glucose below 180 mg/dL.¹ These apply to people with either type 1 or type 2 diabetes who do not have conditions that would make aggressive glucose lowering risky.

A1C reflects an average of blood sugar over the prior two to three months, weighted more toward the recent weeks. The pre-meal and post-meal fingerstick targets give you a narrower, day-to-day picture. Think of A1C as your semester GPA and individual glucose readings as individual test scores. You need both to know how things are going.

Continuous Glucose Monitor Targets

If you wear a continuous glucose monitor, or CGM, the ADA provides a parallel set of targets expressed in terms your device actually shows you. The most important one is time in range, which is the percentage of the day your glucose stays between 70 and 180 mg/dL. For most nonpregnant adults, the goal is to spend more than 70% of the day in that window.² That works out to roughly 17 hours a day at goal.

A less familiar but increasingly emphasized metric is glycemic variability, measured as the coefficient of variation (CV). The target is to keep your CV at or below 36%. Some evidence suggests that getting below 33% may offer extra protection against lows, particularly if you use insulin or a sulfonylurea.³ In practical terms, a low CV means your glucose is spending less time on the roller coaster of spikes and crashes, even if the average looks the same on paper.

Where These Numbers Come From

The 7% A1C threshold is not arbitrary. It rests heavily on two landmark trials that shaped diabetes care for decades. The Diabetes Control and Complications Trial (DCCT) studied people with type 1 diabetes and found that intensive glucose control reduced the risk of developing retinopathy (eye damage) by 76% and slowed its progression by 54% compared with conventional treatment. It also cut the occurrence of kidney damage by 39 to 54% and clinical nerve damage by 60%.⁴ Across the board, intensive therapy reduced early-stage microvascular complications by 35 to 76%, and the benefits were so consistent that the study was stopped a year ahead of schedule.⁵

For type 2 diabetes, the United Kingdom Prospective Diabetes Study (UKPDS) delivered a similar message. Intensive blood glucose control with insulin or oral medications produced a 25% reduction in microvascular endpoints, including the need for laser treatment of the eyes.⁶ A companion study showed that in overweight patients with type 2 diabetes, intensive control may also reduce the risk of heart attacks.⁷ Together, these trials established the principle that keeping glucose close to normal prevents the slow damage to small blood vessels that leads to blindness, kidney failure, and neuropathy.

The Danger of Pushing Too Low

Given that tighter control protects small blood vessels, you might assume that driving A1C as low as possible would be even better. A major trial called ACCORD tested exactly that idea in people with type 2 diabetes who were already at high cardiovascular risk. The intensive arm targeted an A1C below 6%, and the results were alarming. Participants in the intensive group died at a higher rate than those in the standard group, and the intensive strategy had to be stopped early.⁸ The excess deaths were primarily cardiovascular.

Even years after the intensive phase ended, the mortality gap persisted. Follow-up data showed that targeting below 6% reduced nonfatal heart attacks but increased overall death rates, and the researchers concluded that this strategy “cannot be recommended for high-risk patients with advanced type 2 diabetes.”⁹ The ACCORD trial is the main reason the ADA set its general target at 7% rather than something lower. There is a sweet spot. Going well below 7% does not provide proportional additional benefit for most people, and it sharply raises the risk of dangerous low blood sugar episodes that can trigger fatal heart rhythms.

Why Early Control Matters More Than Late Control

One of the most striking findings in diabetes research is the so-called legacy effect. People who achieve good glucose control early in their disease continue to reap benefits long after, even if their control later drifts. A meta-analysis found that intensive glucose lowering reduced major cardiovascular events when studies enrolled people with a diabetes duration under ten years, with an even more pronounced effect in those without pre-existing heart disease.¹⁰ However, the protection did not persist beyond the active treatment period for large-vessel complications, meaning that the microvascular legacy is more robust than the macrovascular one.

Modeling data from newly diagnosed type 2 diabetes reinforces the urgency. Lowering A1C by one percentage point during just the first two years after diagnosis was associated with about a 12% lower cardiovascular risk a decade later. Getting that same reduction during years three and four added another 6%. Altogether, the glucose management achieved within the first four years after diagnosis accounted for roughly 78% of the total cardiovascular benefit achievable over a full decade.¹¹ In plain language, the first few years after diagnosis are disproportionately valuable. Waiting to get serious about blood sugar control costs you more than the same delay would later on.

Adjusted Goals for Older Adults

The ADA does not treat older adults as a monolith. Its 2026 Standards of Care divide older people with diabetes into three tiers based on their overall health, and the glycemic targets differ for each.

Healthy older adults: Those with few chronic illnesses and good cognitive and physical function should still aim for an A1C of 7.0 to 7.5% (or a time in range above 70% if using CGM), with time below 70 mg/dL kept under 4%.
Intermediate health: People with multiple coexisting conditions or moderate functional limitations get a more relaxed target: A1C below 8.0%, or time in range above 50%, with time below range under 1%. The priority shifts toward preventing dangerous lows.
Poor or very complex health: For those with severe frailty, advanced cognitive impairment, or limited life expectancy, the ADA says to focus almost entirely on avoiding hypoglycemia and uncomfortable highs rather than hitting any particular A1C number.

This tiered approach reflects the reality that hypoglycemia is especially dangerous for older adults. A severe low can cause falls, fractures, confusion, and cardiac events. For someone whose remaining life expectancy is short, the long-term microvascular payoff of tight control may never materialize, while the short-term risks of lows are immediate.¹²

Tighter Targets During Pregnancy

Pregnancy flips the calculus entirely. Because even modestly elevated glucose can affect fetal development, the blood sugar targets during pregnancy are substantially lower than the standard adult goals. Current targets call for a fasting glucose at or below 95 mg/dL, a one-hour post-meal reading below 140 mg/dL, and a two-hour post-meal reading below 120 mg/dL.¹³ Some researchers have advocated pushing even lower, with fasting below 90 and one-hour post-meal below 122, though these tighter thresholds remain a topic of active debate. One open question is whether the same targets should apply equally to type 1, type 2, and gestational diabetes, given the very different physiology underlying each.

When Your A1C Does Not Tell the Whole Story

A1C is the cornerstone of diabetes monitoring, but it has well-known blind spots. Any condition that changes the lifespan of red blood cells can push your A1C reading artificially high or low, regardless of what your actual blood sugar has been doing. Iron deficiency anemia, for instance, tends to inflate A1C, while hemolytic anemias (where red blood cells break down faster than normal) tend to lower it. Certain hemoglobin variants, chronic kidney disease, recent blood transfusions, and even pregnancy itself can all distort the result.¹⁴

If your A1C and your daily glucose readings consistently disagree, that discrepancy is worth flagging with your clinician. Someone whose fingerstick or CGM data suggests an average glucose much higher or lower than what their A1C implies may have a condition interfering with the test. In those cases, relying on CGM time-in-range data or fructosamine (an alternative lab test reflecting a shorter window) can give a more accurate picture of control.

How ADA Goals Compare to Other Guidelines

The ADA is not the only organization setting glycemic targets. The American Association of Clinical Endocrinology (AACE, sometimes listed alongside the American College of Endocrinology as AACE/ACE) recommends a somewhat tighter default target of 6.5% or below for A1C.¹⁵ Both organizations agree that targets should be individualized based on safety, and in practice the difference often narrows once patient-specific factors are considered. The ADA’s 7% target is deliberately conservative enough to apply safely to the broadest possible population, including those at higher risk of hypoglycemia. The AACE’s lower number is aimed more at people who can reach it safely, without frequent lows or medication side effects.

Outside the United States, organizations like the European Association for the Study of Diabetes (EASD) typically align with the ADA’s 7% threshold. If you encounter different numbers from different medical societies, the discrepancy is usually not a disagreement about the science. It is a difference in how aggressively each body thinks the default should be set for people who have not yet been individually assessed.

Psychological Distress and Meeting Your Targets

Hitting a glucose target is not purely a matter of medication and diet. Mental health plays a larger role than many people expect. A study of patients with diabetes in Ethiopia found that moderate psychological distress roughly doubled the odds of poor glycemic control, and severe distress nearly tripled them, compared with patients who were mentally well.¹⁶ The relationship runs in both directions: poorly controlled blood sugar can cause fatigue and mood changes that worsen distress, and distress undermines the self-management behaviors that keep blood sugar in check.

The ADA’s Standards of Care acknowledge this loop, recommending that psychosocial care be integrated into diabetes management. If you are consistently missing your targets and cannot figure out why, screening for depression, diabetes distress, or burnout is a legitimate clinical step, not a soft add-on. Glucose numbers do not exist in isolation from the person producing them.

The Economics of Continuous Glucose Monitoring

CGM adoption has exploded in recent years, and one practical question many people face is whether the expense is justified. The answer, at least from a health-economics perspective, increasingly points toward yes. A modeling study of adults with type 2 diabetes on basal insulin found that CGM actually saved money over a ten-year horizon compared with traditional fingerstick monitoring. The higher device costs were more than offset by reduced treatment costs from fewer complications, and the CGM group gained more quality-adjusted life years as well.¹⁷

For adults with type 1 diabetes who still had suboptimal control despite using multiple daily insulin injections, CGM was cost-effective at standard willingness-to-pay thresholds, with improved glucose control and fewer non-severe hypoglycemic episodes.¹⁸ In pediatric type 1 diabetes, pairing CGM with remote patient monitoring (where a care team reviews CGM data between visits) delivered even stronger value, more than tripling the quality-of-life gains at only a modest increase in cost.¹⁹ These findings matter because insurance coverage decisions often hinge on cost-effectiveness data. The trend is clearly moving toward broader coverage, though access still varies depending on your payer and diabetes type.

What CGM gives you in practical terms is the ability to see where you stand relative to those ADA targets in real time. Instead of checking a few snapshots a day with fingersticks and waiting months for an A1C result, you get a running record of time in range, time below range, and glycemic variability. For many people, that feedback loop is what finally makes the abstract A1C goal feel actionable.